Development Overview. The Parties desire and intend to transition the Development of Compounds and Products from Principia to Sanofi (the “Transition”), provided that, before the completion of the Transition, Principia will conduct certain early Development activities set forth in Section 3.2 in coordination with Sanofi.
Appears in 2 contracts
Sources: License Agreement (Principia Biopharma Inc.), License Agreement (Principia Biopharma Inc.)